Literature DB >> 32463083

Prevalence and Factors Associated With Virological Treatment Failure Among Children and Adolescents on Antiretroviral Therapy Attending HIV/AIDS Care and Treatment Clinics in Dodoma Municipality, Central Tanzania.

Niyonziza Z Bitwale1, David P Mnzava2, Francisca D Kimaro1, Theopista Jacob3, Bonaventura C T Mpondo4, Shakilu Jumanne1.   

Abstract

BACKGROUND: As the World Health Organization (WHO) and its joint partners such as USAIDS target achieving 90% sustained virological suppression among children and adolescents living with Human Immunodeficience Virus (HIV)/AIDS, it is imperative to elucidate the current prevalence and factors associated with virological treatment failure for formulation of appropriate strategies. This study was conducted determine the prevalence and factors associated with virological treatment failure among children and adolescents with HIV/AIDS on antiretroviral therapy (ART) attending HIV/AIDS care clinics in Dodoma, Central Tanzania.
METHODS: This was a cross-sectional study of children aged 1-19 years attending 3 HIV/AIDS care clinics in Dodoma (central Tanzania) from November 2018 to February 2019. Sociodemographic and clinical factors were documented, HIV viral load and CD4+ T lymphocytes were evaluated for children on ART for ≥6 months. The primary outcomes were the prevalence and factors associated with viralogic treatment failure.
RESULTS: Of 300 children enrolled, 102 (34%) had virological treatment failure. Poor adherence to ART (adjusted odds ratio [AOR] = 3.221; 95% confidence interval [CI], 1.867-5.558; P = .032), nevirapine regimen (AOR = 3.185; 95% CI, 1.473-6.886; P ≤ .001), not using cotrimoxazole prophylaxis (AOR = 25.56; 95% CI, 3.15-27.55; P = .002) and nondisclosure of HIV status to others (AOR = 7.741; 95% CI, 2.351-25.489; P = .001) were independently associated with virological treatment failure.
CONCLUSIONS: Current prevalence of virological treatment failure among children and adolescents living with HIV on ART remain high. Factors such as ART adherence, nevirapine based regimen, HIV status disclosure to those caring for the child need to be addressed to achieve sustained virological suppression.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV/AIDS; adolescents; antiretroviral therapy; children; virological treatment failure

Year:  2020        PMID: 32463083     DOI: 10.1093/jpids/piaa030

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  5 in total

1.  Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.

Authors:  Taimour Langaee; Mohammad H Al-Shaer; Yan Gong; Elizabeth Lima; Sampson Antwi; Anthony Enimil; Albert Dompreh; Hongmei Yang; Wael A Alghamdi; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Infect Genet Evol       Date:  2021-04-08       Impact factor: 3.342

2.  HIV-1 Treatment Failure, Drug Resistance, and Clinical Outcomes in Perinatally Infected Children and Adolescents Failing First-Line Antiretroviral Therapy in Western Kenya.

Authors:  Winstone Nyandiko; Sabina Holland; Rachel Vreeman; Allison K DeLong; Akarsh Manne; Vladimir Novitsky; Festus Sang; Celestine Ashimosi; Anthony Ngeresa; Ashley Chory; Josephine Aluoch; Millicent Orido; Eslyne Jepkemboi; Soya S Sam; Angela M Caliendo; Samuel Ayaya; Joseph W Hogan; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2022-02-01       Impact factor: 3.771

3.  Determinants of Virological Failure Among HIV-Infected Children on First-Line Antiretroviral Therapy in West Gojjam Zone, Amhara Region, Ethiopia.

Authors:  Awoke Shumetie; Nurilign Abebe Moges; Muluken Teshome; Getnet Gedif
Journal:  HIV AIDS (Auckl)       Date:  2021-12-14

4.  Treatment failure and its associated factors among children receiving highly active antiretroviral therapy in Ethiopia: A systematic review and meta-analysis.

Authors:  Temesgen Getaneh; Ayenew Negesse; Getenet Dessie; Melaku Desta; Moges Agazhe Assemie; Agimasie Tigabu; Kihinetu Gelaye; Addisu Alehegn Alemu; Sarah Lebu
Journal:  SAGE Open Med       Date:  2022-02-28

5.  Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis.

Authors:  Julie Jesson; Siobhan Crichton; Matteo Quartagno; Marcel Yotebieng; Elaine J Abrams; Kulkanya Chokephaibulkit; Sophie Le Coeur; Marie-Hélène Aké-Assi; Kunjal Patel; Jorge Pinto; Mary Paul; Rachel Vreeman; Mary-Ann Davies; Jihane Ben-Farhat; Russell Van Dyke; Ali Judd; Lynne Mofenson; Marissa Vicari; George Seage; Linda-Gail Bekker; Shaffiq Essajee; Diana Gibb; Martina Penazzato; Intira Jeannie Collins; Kara Wools-Kaloustian; Amy Slogrove; Kate Powis; Paige Williams; Mogomotsi Matshaba; Lineo Thahane; Phoebe Nyasulu; Bhekumusa Lukhele; Lumumba Mwita; Adeodata Kekitiinwa-Rukyalekere; Sebastian Wanless; Tessa Goetghebuer; Claire Thorne; Josiane Warszawski; Luisa Galli; Annemarie M C van Rossum; Carlo Giaquinto; Magdalena Marczynska; Laura Marques; Filipa Prata; Luminita Ene; Lyuba Okhonskaya; Marisa Navarro; Antoinette Frick; Lars Naver; Christian Kahlert; Alla Volokha; Elizabeth Chappell; Jean William Pape; Vanessa Rouzier; Adias Marcelin; Regina Succi; Annette H Sohn; Azar Kariminia; Andrew Edmonds; Patricia Lelo; Rita Lyamuya; Edith Apondi Ogalo; Francesca Akoth Odhiambo; Andreas D Haas; Carolyn Bolton; Josephine Muhairwe; Hannock Tweya; Mariam Sylla; Marceline D'Almeida; Lorna Renner; Mark J Abzug; James Oleske; Murli Purswani; Chloe Teasdale; Harriet Nuwagaba-Biribonwoha; Ruth Goodall; Valériane Leroy
Journal:  J Int AIDS Soc       Date:  2022-03       Impact factor: 6.707

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.